Best Life Sciences Companies in Montreal, Canada
The 148 best Life Sciences companies in Montreal, Canada in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: DalCor.
Our analysis of 50 Life Sciences companies
$27.5b in tracked funding; 76% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Montreal
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | DalCor Developer of small molecules therapeutics for cardiovascular diseases | $234M | 33 mo ago | Series D | 1 | — | — | — | — |
| 2 | Milestone Pharmaceuticals Provider of small molecule based drug development for treating cardio vascular conditions | $174M | 38 mo ago | Public | 39 | — | Top 10M | 115 patents Water‑soluble short‑acting phenylalkylamine calcium‑channel blocker salts for drug formulation | 1 partnership |
| 3 | Repare Therapeutics Developer of targeted therapies to address the genetic alterations associated with selected tumors | $166M | 72 mo ago | Acquired | 180 | Daniel Durocher Co-Founder | — | 161 patents Small‑molecule kinase inhibitors for cancer therapy, focusing on PLK4, ATR, MYT1 targets. | — |
| 4 | Inversago Pharma Peripheral cannabinoid (CB1) receptor antagonist/inverse agonist for the treatment of metabolic diseases | $115M | 44 mo ago | Series C | 25 | — | — | 20 patents Development of small‑molecule CB1 receptor antagonists and related heterocyclic drug candidates | — |
| 5 | Congruence Therapeutics Developer of therapeutics for the treatment of rare diseases 50AI top 20%Funding top 24%Moat top 31%Talent top 38% All 8 signals ▾AItop 20% Fundingtop 24% Moattop 31% Talenttop 38% Marketbottom 38% Globalbottom 38% Techbottom 31% Newsbottom 22% AI: Classified as an AI company Funding: Raised $65.0M across 4 rounds · 4 rounds over 4 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 50/100 | $65M | 2 mo ago | Series B | 33 | Michael Goldsmith Co-Founder | Top 50M | — | — |
| 6 | Nomic Provider of next-generation proteomics platform for drug discovery and protein analysis 60Funding top 27%Growth top 28%Talent top 28%Moat top 39% All 8 signals ▾Fundingtop 27% Growthtop 28% Talenttop 28% Moattop 39% Techtop 46% Globalbottom 43% Marketbottom 39% Newsbottom 18% Funding: Raised $63.0M across 2 rounds · 2 rounds over 6 yrs (0.3/yr) Growth: Web rank 50,000,000 → 10,000,000 YoY · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 60/100 | $63M | 21 mo ago | Series B | 43 | Jeff Munzar Co-Founder & CTO | Top 10M | — | 1 partnership |
| 7 | Methylgene Developer of therapeutics for cancer and infectious diseases | $62M | 162 mo ago | Acquired | — | Charles Grubsztajn CEO | — | 412 patents Small-molecule kinase and HDAC inhibitor therapeutics for oncology | — |
| 8 | Morphocell Technologies Developer of an engineered liver for the treatment of liver diseases 45Talent top 28%Funding top 31%Growth top 35%Moat top 42% All 7 signals ▾Talenttop 28% Fundingtop 31% Growthtop 35% Moattop 42% Techtop 49% Globalbottom 36% Marketbottom 25% Talent: Analyst team rating 4/5 Funding: Raised $50.0M across 2 rounds · 2 rounds over 5 yrs (0.4/yr) rank vs industry peers · Fliar Intelligence Index 45/100 | $50M | 6 mo ago | Series A | 9 | — | Top 50M | — | 1 expansion · 1 award |
| 9 | Sollum Technologies Dynamic LED lighting solutions for greenhouses, optimizing plant growth and productivity 57Talent top 28%Funding top 31%Moat top 39%Tech top 44% All 9 signals ▾Talenttop 28% Fundingtop 31% Moattop 39% Techtop 44% Growthtop 45% AItop 45% Marketbottom 39% Globalbottom 29% Newsbottom 18% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $42.0M across 8 rounds · 8 rounds over 9 yrs (0.9/yr) rank vs industry peers · Fliar Intelligence Index 57/100 | $42M | 41 mo ago | Series B | 45 | Gabriel Dupras Co-founder | Top 10M | — | — |
| 10 | KisoJi Developer of multi-specific antibodies for cancer treatment | $41M | 20 mo ago | Series B | — | David Young Co-Founder & CEO | — | — | — |
| 11 | Aegera Therapeutics Developing novel small molecule therapeutics against cancer and immune diseases | $38M | 200 mo ago | Acquired | 1,300 | — | — | 140 patents Small‑molecule IAP/BIR domain inhibitors for neuro‑pain, MS diagnostics, and related therapeutics | — |
| 12 | Ability Developer of modulating biotherapeutics to address cancer and autoimmune diseases | $30M | 24 mo ago | Seed | — | Jean Buerckert Co-Founder & CTO | Top 50M | — | 1 internship |
| 13 | PreciThera Developer of precision medicine for rare genetic bone diseases | $29M | 106 mo ago | Series A | 4 | — | — | 8 patents Therapeutic TGF‑β antagonist conjugates and fusion proteins for signaling inhibition | — |
| 14 | Sunshine Biopharma Developer of antiviral and anticancer drugs | $28M | 37 mo ago | Public | 46 | — | Top 10M | 2 patents Patents concentrated in health & consumer products | — |
| 15 | A Better Life Pharma Developer of cannabinoid-based therapeutics for neurological disorders 24Growth top 35%Funding top 36%News top 39%Tech bottom 48% All 7 signals ▾Growthtop 35% Fundingtop 36% Newstop 39% Techbottom 48% Globalbottom 43% Talentbottom 41% Marketbottom 11% Growth: Fresh capital in last 24 mo Funding: Raised $25.7M across 14 rounds · 14 rounds over 6 yrs (2.3/yr) rank vs industry peers · Fliar Intelligence Index 24/100 | $26M | 13 mo ago | Public | 4 | Ahmad Doroudian Founder & CEO | Top 50M | — | — |
| 16 | Puzzle Medical Devices Developer of a minimally invasive heart pump 57Patents top 24%Talent top 28%Innovation top 31%Moat top 31% All 9 signals ▾Patentstop 24% Talenttop 28% Innovationtop 31% Moattop 31% Growthtop 35% Fundingtop 37% Techbottom 48% Globalbottom 42% Marketbottom 35% Patents: 64 patents matched (strict assignee match) · 50 filings since 2022 vs 14 in 2017-21 Talent: 3 named leaders on record · 3 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 57/100 | $25M | 15 mo ago | Series B | 24 | Gabriel Georges Co-Founder | Top 10M | 64 patents Implantable modular fluid‑flow control and drug‑delivery pump systems for medical use | 3 job openings |
| 17 | Thryv Therapeutics Provider of precision medicines for cardiovascular and related diseases | $24M | 36 mo ago | Series A | 22 | Paul Truex CEO | Top 10M | 17 patents Small-molecule SGK-1 kinase inhibitors for cancer treatment | — |
| 18 | Optina Diagnostics Developer of eye-scanning devices for Alzheimer's disease | $24M | 52 mo ago | Series A | 42 | David LaPointe CEO | — | 32 patents Advanced multispectral retinal imaging and AI-driven biomarker detection for eye diagnostics | — |
| 19 | Soundbite Medical Shockwave device to treat chronic total occlusions in the coronary and peripheral vasculature | $22M | 97 mo ago | Series A | 18 | Louis-Philippe Riel Co-Founder and Director Disposables & Systems | — | — | — |
| 20 | Allostera Pharma New class of pre-clinical drugs, called Allosteramers primarily focused on inflammation and autoimmunity | $16M | 202 mo ago | Deadpooled | — | Sylvain Chemtob Co-Founder | — | — | — |
| 21 | MeaCor Developing a transcatheter heart valve repair device to treat valvular disease | $15M | 25 mo ago | Series A | 2 | — | — | 3 patents Provides minimally invasive surgical instrument support and helical anchor deployment systems. | — |
| 22 | Alethia BioTherapeutics Developing monoclonal antibody-based therapeutics for cancer-associated diseases. | $14M | 20 mo ago | Series C | 12 | — | — | 205 patents Engineered peptide immunotherapies enhancing tumor-infiltrating lymphocyte infiltration. | — |
| 23 | AngioChem Develops Peptide drug conjugates for the treatment of neurological diseases | $14M | 84 mo ago | Series C | 11 | Robert Dugré ex-CEO | — | 328 patents Targeted antibody‑peptide conjugates for leptomeningeal cancer therapy | — |
| 24 | GLyPharma Therapeutic Developer of therapeutics for the treatment of cancer | $12M | 94 mo ago | Acqui-Hired | 3 | — | — | — | — |
| 25 | Earth Alive Clean Technologies Biotech company addressing environmental challenges in agriculture, mining, and industry | $12M | 63 mo ago | Public | 11 | David Gilmour CEO | Top 50M | — | 1 partnership |
| 26 | Reliant AI Provider of an AI platform for biopharmaceutical research and development | $11M | 22 mo ago | Acquired | — | Karl Hermann Co-Founder & CEO | Top 10M | — | 1 partnership |
| 27 | Valence Labs AI research engine focusing on advancing drug discovery through computational biology | $8M | 54 mo ago | Acquired | 27 | Therence Bois Co-Founder & COO | Top 10M | — | 1 launch |
| 28 | Noze Developer of a breath-based diagnostic platform to detect disease markers noninvasively | $7M | 22 mo ago | Seed | 54 | Ashok Masilamani Chief Technology Officer and Founder | Top 50M | — | — |
| 29 | My Intelligent Machines Provider of AI powered platform for life science researcher | $7M | 62 mo ago | Seed | 33 | — | — | — | — |
| 30 | Eli Provider of AI-base smart devices for women to monitor reproductive health 72Innovation top 25%Growth top 25%News top 25%Tech top 31% All 11 signals ▾Innovationtop 25% Growthtop 25% Newstop 25% Techtop 31% Talenttop 38% Fundingtop 40% Moattop 44% AItop 45% Producttop 46% Globalbottom 39% Marketbottom 31% Innovation: 4 new-product events in 24 mo · Deep-tech classification: Tech Hardware Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 72/100 | $7M | 12 mo ago | Series A | 19 | Marina Rivas Co-Founder & CEO | Top 5M | — | — |
| 31 | Liphorus Pharmaceuticals Small molecule targeting PCSK9 for the treatment of hypercholesterolemia | $6M | 139 mo ago | Series A | — | Andrew Jennings Co-Founder | — | — | — |
| 32 | Avitia Provider of AI-powered diagnostics platform for molecular cancer testing solutions | $5M | 15 mo ago | Seed | — | James Lumsdaine Chief Executive Officer | Top 50M | — | — |
| 33 | Prognomix Offers a diagnostic and predictive technology targeting Type 2 diabetes patients | $4M | 230 mo ago | Deadpooled | — | Normand Balthazard ex-CEO | — | — | — |
| 34 | CelluForce Provides Cellulose NanoCrystals (CNC) solutions | $4M | 134 mo ago | Series A | 14 | — | Top 10M | — | 4 launchs |
| 35 | Sema Thera SEMA 3A TRAP inhibitors for the treatment of various retinopathies including diabetic macular edema. | $3M | 99 mo ago | Series A | 6 | — | — | — | — |
| 36 | Gladius Pharma Canadian, early stage biopharma developing modified beta-lactam compounds for MDR gram-negative infections | $3M | 131 mo ago | Deadpooled | 6 | Michael Atkin President & CEO | — | — | — |
| 37 | Remedium AI Provider of an AI-based platform for drug discovery | $3M | — | Seed | — | Robert Murgita Founder | — | — | — |
| 38 | FemTherapeutics Provider of personalized medicine for pelvic health of the women | $2M | 36 mo ago | Seed | 8 | Inara Lalani Co-Founder | Top 50M | 7 patents Patents concentrated in health & consumer products | — |
| 39 | Montrium Cloud-based regulatory document quality & content management platform for life sciences industries | $2M | 58 mo ago | Funding Raised | 64 | — | Top 50M | — | — |
| 40 | Mimetogen Pharmaceuticals Peptidomimetics as a novel approach to treating ophthalmic diseases | $2M | 183 mo ago | Series B | 3 | — | — | 56 patents Beta-turn peptidomimetic cyclic salt synthesis for therapeutic peptide drugs | — |
| 41 | Laurent Pharma Canadian, early-stage, private orphan drug company developing oral therapies to modulate the… | $2M | 72 mo ago | Series A | 7 | — | — | — | — |
| 42 | Thorasys Airway oscillometry to measure lung fuction | $2M | 117 mo ago | Seed | 41 | Thomas Schuessler Founder & CEO | Top 50M | — | — |
| 43 | Simmunome Provider of an AI-powered computational models for clinical trial study | $2M | 33 mo ago | Seed | 5 | Armstrong Murira Co-Founder & CEO | Top 50M | — | — |
| 44 | Leap Medical A non-invasive device to detect brain injuries and infections | $1M | 194 mo ago | Deadpooled | — | Victor Lanzo Co-Founder & CEO | — | — | — |
| 45 | SOLABS Enterprise Quality Management System for Life Sciences Industry | $1M | 207 mo ago | Series A | 28 | — | Top 50M | — | 3 partnerships |
| 46 | NexPlasmaGen Developer of cold plasma delivery system for treating breast cancer | $795K | 94 mo ago | Seed | 2 | Valerie Leveille Founder & President | — | 9 patents Plasma generation devices and medical plasma cancer treatment technologies | 1 award |
| 47 | Starpax Biopharma Developer of therapeutics for the treatment of cancer | $782K | 16 mo ago | Seed | — | Michael Gareau Founder & CEO | Top 50M | 20 patents Magnetic navigation and control of therapeutic agents for targeted drug delivery | — |
| 48 | Noveko International Air filters and ultrasound scanners | $548K | 68 mo ago | Public | — | Andre Leroux CEO & Chairman | — | 15 patents Antimicrobial textile fibers and microbicidal air filtration technologies | — |
| 49 | Relevium technologies Provider of magnetic wearable devices for pain relief and rehabilitation | $400K | 72 mo ago | Public | — | Aurelio Useche CEO | — | — | — |
| 50 | Modulari-T Biosciences Developer of cell therapies for immune disorders | $125K | 36 mo ago | Seed | 5 | David White Co-Founder | Top 50M | — | 1 launch · 1 award |
Top 12 Life Sciences companies in Montreal
#1
Series B · Montreal, Quebec · founded 2021 · 33 employees$65Mraised▾
Developer of therapeutics for the treatment of rare diseases. It offers an in-silico platform that enables the design of small molecules that stabilizes misfolded proteins to treat rare diseases. It offers computational drug discovery engine called Revenir which captures the biophysical changes caused by mutations in proteins. It examines surface features and numerous biophysical descriptors of both the mutated and wild-type proteins. It offers a lead candidate CGX-926 for obesity.
- Mar 2026Series B$39.5M
- Sep 2025Series B$32M
- Mar 2023Series A$15M
- Feb 2022Series A$50M
#2
Series A · Montreal, Montreal · founded 2018 · 9 employees$50Mraised▾
Developer of an engineered liver for the treatment of liver diseases. The company's technology ReLiver is an engineered liver tissue that is used to develop an implantable device for acute-on-chronic liver failure, an extracorporeal bio-artificial liver device, and an in vitro assay for next-generation drug discovery.
- Dec 2025Series A$10M
- Feb 2024Series A$40M
- Jul 2021Seed—
#3
Public · Montreal, Montreal · founded 2019 · 4 employees$25.7Mraised▾
Developer of cannabinoid-based therapeutics for neurological disorders. It has developed the commercialization of premium cannabinoid-based nutraceuticals and pharmaceutical products. Its product pipeline includes TD-0148A a non-hallucinogenic second-generation Lysergic Acid Diethylamide (“LSD”) derivative designed for the treatment of depression, post-traumatic stress disorder (“PTSD”), TD-010 for anxiety, and other neuropsychiatric disorders. and AP-003 is developed to check the therapeutic efficacy of IFNa2b in COVID-19 disease. It produces cannabinoid powder for use in capsules, stick packs, bulk powder, beverages, baked goods, and many more.
- Apr 2025Post IPO$1.1M
- Jun 2024Post IPO$175K
- May 2024Post IPO$530K
- Apr 2024Post IPO$1.2M
#4
Series B · Montreal, Montreal · founded 2018 · 24 employees$25Mraised▾
Developer of a minimally invasive heart pump. The company has developed a minimally invasive long-term hemodynamic transcatheter pump heart for treating patients with end-stage heart failure.
- Mar 2025Series B$5.5M
- Jan 2025Series B$30M
- Feb 2023Series A$25M
- Jan 2022Seed—
#5
Series B · Montreal, Quebec · founded 2017 · 43 employees$63Mraised▾
Provider of next-generation proteomics platform for drug discovery and protein analysis. The company has developed the nELISA, a next-generation ELISA platform by using DNA nanotechnology for measuring proteins and applicable for a wide variety of use cases within drug and biomarker development workflows.
- Sep 2024Series B$42M
- Dec 2021Series A$17M
- 2020Seed—
#6
Series A · Montreal, Montreal · founded 2019 · 19 employees$6.6Mraised▾
Eli is a provider of AI-based smart devices for women to monitor reproductive health. The platform provides a point-of-care device for women to get their everyday hormone profile, at home, from a saliva sample. The device helps to monitor their reproductive lives, including contraception, fertility, and menopause. It also provides an AI-based mobile app that enables users to interpret the information collected by the device and make informed decisions.
- Jun 2025Series A$12M
- Jan 2025Seed$1.1M
- Apr 2023Seed$3.7M
- Dec 2020Seed$1.5M
#7
Series B · Montreal, Quebec · founded 2009$41.3Mraised▾
Developer of multi-specific antibodies for cancer treatment. It offers tri-specific immuno-oncology antibody candidates which include KJ-101 for neuroendocrine solid tumors, KJ-102 for acute myeloid leukemia, and KJ-103 for TROP-2 Expressing solid tumors.
- Oct 2024Series B$40.6M
- Jun 2018Series A—
- Oct 2016Seed$751.9K
#8
Series D · Montreal, Montreal · founded 2015 · 1 employees$233.9Mraised▾
DalCor Pharmaceuticals develops small molecule therapeutics for cardiovascular diseases. Its lead candidate Dalcetrapib is a cholesterol ester transfer protein (CETP) inhibitor to treat the cardiovascular disease risk caused by the mutations in the ADCY9 gene. Dalcetrapib is currently in phase III trials for the treatment of a genetic subpopulation of patients suffering from Acute Coronary Syndrome (ACS).
- Sep 2023Series D$80M
- May 2020Series B$3.9M
- May 2020Conventional Debt—
- Apr 2016Series B$100M
#9
Series C · Montreal, Montreal · founded 2002 · 12 employees$13.9Mraised▾
Alethia Biotherapeutics engages in the discovery and development of therapeutic monoclonal antibodies (mAb) against highly-disease tissue-specific novel clinically-relevant targets. The company focuses on bone loss in acute disorders, invasive carcinomas, and cancer-associated epithelial-to-mesenchymal transition. Its products include AB-25E9, a bone antiresorptive and humanized IgG2 that inhibits the function of Siglec-15 and is used for the treatment of patients with acute bone loss; AB-3A4, an antibody-drug conjugate (ADC) representing a completely new therapeutic approach for treatment of invasive carcinomas; and AB-16B5, an humanized IgG2 monoclonal antibody and EMT inhibitor that targets tumor-associated secreted clusterins.
- Oct 2024Series C$5.1M
- Aug 2023Series C$6M
- Nov 2012Series B$4.7M
- Sep 2010Series A$9.2M
#10
Seed · Montreal, Quebec · founded 2025$5Mraised▾
Provider of AI-powered diagnostics platform for molecular cancer testing solutions. The platform delivers actionable insights, real-time genomic data access, and clinical insights to assist treatment decision-making. It offers ready-to-use NGS-based tissue and liquid biopsy panels that integrate into existing workflows. The platform also identifies personalized treatment options and connects to localized clinical trials.
- Feb 2025Seed$5M
#11
Public · Montreal, Montreal · founded 2005 · 39 employees$174.5Mraised▾
Provider of small molecule based drug development for treating cardio vascular conditions. The company's lead product is a novel and potent short-acting calcium channel antagonist for the systemic treatment of transient cardiovascular conditions such as atrial arrhythmias and angina. The product is being developed as a nasal spray to provide for rapid systemic drug delivery.
- Mar 2023Post IPO$125M
- Jul 2020Post IPO$18.6M
- Oct 2018Series D$80M
- Aug 2017Series C$55M
#12
Acquired · Montreal, Quebec · founded 2023$11.3Mraised▾
Provider of an AI platform for biopharmaceutical research and development. It offers a flagship product, Reliant Tabular that streamline the process of finding scientific evidence for decision-making, reducing data processing time. It combines an AI engine with customized tools to assist with portfolio strategy and launch success prediction. The platform automates data ingestion and extraction, and provides knowledge graphs to map relationships between trials and mechanisms.
- Aug 2024Seed$11.3M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
What Montreal researches in biotechnology
Montreal's top institutions—MCRI, MNI, and Montreal Children's Hospital—optimistically advance biotechnology through recent, breakthrough-focused research on gene regulation, RNA splicing, and rare metabolic and immune disorders.
- Montreal Clinical Research Institute9
- Montreal Neurological Institute and Hospital8
- Montreal Children\'s Hospital2
- Montreal Biodome1
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.